Phase II study of the pharmacokinetics of nevirapine and the incidence of nevirapine resistance mutations in HIV-infected women receiving a single intrapartum dose of nevirapine with the concomitant administration of zidovudine/didanosine or zidovudine/didanosine/lopinavir/ritonavir

Trial Profile

Phase II study of the pharmacokinetics of nevirapine and the incidence of nevirapine resistance mutations in HIV-infected women receiving a single intrapartum dose of nevirapine with the concomitant administration of zidovudine/didanosine or zidovudine/didanosine/lopinavir/ritonavir

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Nevirapine (Primary) ; Didanosine; Lopinavir/ritonavir; Zidovudine
  • Indications HIV infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2012 Primary drug tag added, completion date updated
    • 06 Dec 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 01 Nov 2009 ClinicalTrials.gov reports study completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top